InsidersTradesSigma
Follow the Orasure Technologies INC stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Orasure Technologies INC has recorded 87 insider filings. Market capitalisation: €292.6m. The latest transaction was reported on 15 May 2025 (Retenue fiscale). Among the most active insiders: Anthony Michele Marie. The full history is openly available.
87
Insider Decl.
n/a
Thresholds
€1m
11 ops.
Buy Volume
n/a
n/a
Sell Volume
53Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,265 of 29,057 companies
17.4
score / 100
Value10
Quality25
FCF yld-19%
Earn yld-25%
EV/EBITDA·
ROE-21%
Gross mgn42%
Net mgn-60%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 May 2025
Declarations87 total
4,999 shares@ US$2.652519.1% of flowCommon StockSEC:0001062993-25-009563:0
7,977 shares@ US$2.652511.6% of flowCommon StockSEC:0001062993-25-009564:0
6,666 shares@ US$2.652515.6% of flowCommon StockSEC:0001062993-25-009562:0
4,387 shares@ US$2.65254.7% of flowCommon StockSEC:0001062993-25-009566:0
6,427 shares@ US$2.652520.5% of flowCommon StockSEC:0001062993-25-009565:0
71,017 shares0Common StockSEC:0001062993-25-009567:0
1,385 shares@ US$3.55251.9% of flowCommon StockSEC:0001062993-25-006390:0
100,647 shares0Common StockSEC:0001062993-25-004318:0
462,414 shares0Common StockSEC:0001062993-25-004316:0
52,166 shares0Common StockSEC:0001062993-25-004314:0
88,148 shares0Common StockSEC:0001062993-25-004319:0
28,670 shares@ US$3.48894.2% of flowCommon StockSEC:0001062993-25-004056:0
Canonical exit: 29 May 2025 (T+90)
12,750 shares@ US$3.0817.1% of flowCommon StockSEC:0001062993-25-004057:0
Canonical exit: 28 May 2025 (T+90)
78,625 shares@ US$3.146310.3% of flowCommon StockSEC:0001062993-25-003843:0
Canonical exit: 28 May 2025 (T+90)
47,659 shares@ US$3.172960.4% of flowCommon StockSEC:0001062993-25-003842:0
Canonical exit: 28 May 2025 (T+90)
7,000 shares@ US$3.0612.5% of flowCommon StockSEC:0001062993-25-003783:0
Canonical exit: 28 May 2025 (T+90)
64,000 shares@ US$3.151316.0% of flowCommon StockSEC:0001062993-25-003840:0
Canonical exit: 28 May 2025 (T+90)
766 shares@ US$3.95252.9% of flowCommon StockSEC:0001062993-25-001673:0
35,083 shares0Common StockSEC:0001062993-25-001674:0
4,822 shares@ US$3.77517.8% of flowCommon StockSEC:0001062993-25-000490:0
6,859 shares@ US$3.7753.2% of flowCommon StockSEC:0001062993-25-000492:0
23,256 shares@ US$4.3037.7% of flowCommon StockSEC:0001062993-24-016411:0
19,118 shares@ US$4.596.7% of flowCommon StockSEC:0001062993-24-014759:0
401,618 shares@ US$4.6574.9% of flowCommon StockSEC:0001062993-24-012025:0
5,364 shares@ US$5.26510.1% of flowCommon StockSEC:0001062993-24-010480:0
25 of 87 declarations
关于 Orasure Technologies INC
OraSure Technologies Inc. (NASDAQ: OSUR) 是一家总部位于美国宾夕法尼亚州伯利恒的美国诊断和样本采集公司。该公司成立于1987年，最初名为SolarCare，于2000年进入公开市场时更名为OraSure Technologies。对于欧洲的法语投资者而言，OraSure可被视为一家专注于分散式检测的专业医疗保健工具公司，即设计用于即时护理、居家或近患者环境的诊断产品。 该业务围绕两个核心支柱组织：诊断和样本管理解决方案。在诊断方面，OraSure销售快速检测和相关设备，涵盖多个临床领域，包括HIV、丙型肝炎、COVID-19、梅毒、镰状细胞病以及历史上的埃博拉。在样本管理方面，该公司提供收集和稳定技术，可保存唾液、口腔液、尿液、皮肤细胞、血液和粪便等多种样本类型中的DNA和RNA。该平台具有战略重要性，因为它将公司的业务范围扩展到基因组学研究、实验室工作流程和专业临床应用。 从竞争角度来看，OraSure在快速诊断和样本采集领域占据利基市场，其OraQuick品牌及其采集技术拥有广受认可的品牌特许经营权。然而，该公司在一个拥挤且受到严格监管的市场中运营，报销动态、公共卫生资金和监管批准对需求产生重大影响。近期业绩表明，该业务已从疫情期间COVID收入激增中转型；与此同时，基础核心业务相对更稳定，诊断业务在2025年初显示出同比增长，尽管由于COVID相关销售额急剧下降导致总收入下降。 从地理上看，OraSure总部位于宾夕法尼亚州伯利恒，并通过加拿大渥太华的DNA Genotek、美国和英国的Sherlock Biosciences以及北卡罗来纳州的BioMedomics开展额外业务。这一足迹支持产品开发和国际商业化。2025年和2026年初的最新公司更新强调了管理层通过新产品里程碑推动增长加速的努力，包括用于衣原体和淋病快速分子自检以及用于性传播感染检测的Colli-Pee™家用尿液采集设备。管理层还提及了一项40 million美元的股票回购计划，这表明在执行力提高的同时，公司愿意回馈资本。 总体而言，OraSure Technologies是一家在纳斯达克上市的美国小型医疗保健诊断公司，对创新、监管时机和后疫情时代的正常化具有重要影响。对于关注SEC Form 4内部交易活动的投资者而言，该股票可被视为一个由催化剂驱动的诊断平台，既具有运营杠杆，也存在较高的执行风险。
